Artigo Revisado por pares

Pharmacotherapy in Adults With ADHD

1997; Slack Incorporated (United States); Volume: 27; Issue: 8 Linguagem: Inglês

10.3928/0048-5713-19970801-07

ISSN

1938-2456

Autores

Amar N. Bhandary, Francisco Arnalich, Robert J. Gregory, Phebe Tucker, Prakash S. Masand,

Tópico(s)

Pharmaceutical studies and practices

Resumo

ATTENTION DEFICIT HYPERACTIVITY DISORDER IN ADULTHOODPharmacotherapy in Adults With ADHD Amar N Bhandary, MD, , , MD Francisco Fernandez, MD, , , MD Robert J Gregory, MD, , , MD Phebe Tucker, MD, , and , MD Prakash Masand, MD, , MD Amar N Bhandary, MD , Francisco Fernandez, MD , Robert J Gregory, MD , Phebe Tucker, MD , and Prakash Masand, MD Published OnlineAugust 01, 1997https://doi.org/10.3928/0048-5713-19970801-07PDFView Full Text ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1. Bellak L, Black RB. Attention deficit hyperactivity disorder in adults. Clin Then 1992; 14:138-147. Google Scholar2. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Press; 1994:78-85. Google Scholar3. Weiss G, Hechtmann L, Milroy T, et al. Psychiatric status of hyperactives as adults: a controlled fifteen year followup of sixty-three hyperactive children. J Am Acad Child Psychiatry. 1985;24:211-223. Google Scholar4. Denckla MB. Attention deficit hyperactivity disorder residual type. J Child Neurol. 1991; 6(suppl):S44-S50. Google Scholar5. Hunt RD, Mandi L, Lau S, et al. Neurobiologica] theories of ADHD. In: Greenhill LL, Osman BB, eds. Ritalin: Theory and Patient Management. New York, NY: Mary Ann Liebert Inc; 1991:267-288. Google Scholar6. Chelune GJ, Ferguson W, Koon R, et al. Frontal lobe disinhibition in attention deficit disorder. Child Psychiatry Hum Dev. 1986; 16:221-234. Google Scholar7. Bhandary AN, Gregory RJ, Carmen L, et al. Psychostimulants and beta blockers; combination pharmacotherapy for attention deficit hyperactivity disorder. Annual meeting American Psychiatric Association; Miami, Fla; May 22, 1995. Google Scholar8. Ratey JJ, Greenburg MS, Lindem KJ. Combination of treatments for attention deficit hyperactivity disorder in adults. J Nerv Ment Dis. 1991; 179:699-701. Google Scholar9. Anderson GM. Reviewing the role of serotonin in disruptive behaviors. J Child Adolesc Psychoph, 1993; 3:vii-ix. Google Scholar10. Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry. 1937; 94:577-585. Google Scholar11. Hill D. Amphetamine in psychopathic states. Brit J Addictions. 1947; 44:50-54. Google Scholar12. Arnold LD, Strobl D, Weisenberg A. A hyperkinetic adult: study of the paradoxical amphetamine response. JAMA. 1972; 222:693-694. Google Scholar13. Gomez RL, Janowsky D, Zeitin M, et al. Adult psychiatric diagnosis and symptoms compatible with the hyperactive child syndrome: a retrospective study. J Clin Psychiatry. 1981; 42:389-394. Google Scholar14. Shekim WO, Asarnow RF, Hess E, et al. The clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder residual state. Compr Psychiatry. 1990; 31:416-425. Google Scholar15. Bhandary AN. The adulthood syndrome of attention deficit hyperactivity disorder. J Pract Psych Beh Health. In press. Google Scholar16. Wender PH. Attention Deficit Disorder in Adults. New York, NY: Oxford University Press; 1995:144-197. Google Scholar17. Green WH. Non-stimulant drugs in treatment of attention deficit hyperactivity disorder in children and adolescents. Psychiatr Clin North Am. 1992; 2:449-465. Google Scholar18. Hunt H, Lau S, Ryu J. Alternative therapies for ADHD. In: Osman BB, Greenhill LL, eds. Ritalin: Theory and Patient Management. New York, NY: Mary Ann Liebert; 1991:75-96. Google Scholar19. Wilens TD, Spencer TJ, Biederman M. Pharmacotherapy of adult attention deficit hyperactivity disorder. Progress Notes; American Society of Clinical Psychopharmacology. 1994; 5:1-4. Google Scholar20. Greenhill LL. Attention deficit hyperactivity disorder; the stimulants. Child Adolesc Psych Clin North Am. 1995;4:123-168. Google Scholar21. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am. 1992;15:191-122. Google Scholar22. Wood DR, Reimherr FW, Wender PH, et al. Diagnosis and treatment of minimal brain dysfunction in adults. Arch Gen Psychiatry. 1976; 33;1453-1460. Google Scholar23. Wender PH, Reimherr FW, Wood D, et al. A controlled study of methylphenidate in the treatment of attention deficit disorder residual type in adults. Am J Psychiatry. 1985; 142:547-552. Google Scholar24. Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry. 1984; 41:1059-1063. Google Scholar25. Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorder in adults. Clin Neuropharmacol. 1985; 8:343-356. Google Scholar26. Spencer T, Wilens TE, Biederman J, et al. A double blind comparison of methylphenidate and placebo in adults with adult deficit hyperactivity disorder. Arch Gen Psychiatry. 1995; 52:350-353. Google Scholar27. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder ('minimal brain dysfunction') in adults: a replication study of diagnosis and drug treatment. Arch Gen Psychiatry. 1981; 38:449-456. Google Scholar28. Caresia L, Pugnetti L, Bessana R, et al. EEG and clinical findings during pemoline treatment in children and adults with adult deficit disorder; an 8 week open trial. Neuropsychobiology. 1984; 11:158-167. Google Scholar29. Clinical use of methamphetamine in attention deficit disorder (ADD). Abbott Park, ??: Abbott Laboratories; 1994. Google Scholar30. Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry, a consideration. Arch Gen Psychiatry. 1981; 38:449-456. Google Scholar31. Sprague RL, Sleator EK. Methylphenidate in hyperactive children: differences in dose effects on learning and social behaviors. Science. 1977; 38:1274-1276. Google Scholar32. Physician's Desk Reference. 50th ed. Oradell, NJ: Medical Economics; 1996. Google Scholar33. Barkley RA, Du Paul GJ, McMurray MB, et al. Attention deficit disorder with and without hyperactivity; clinical response to three dose levels of methylphenidate. Pediatrics. 1991; 87:519-531. Google Scholar34. Ratey JJ, Hallowell E, Leveroni CL. Pharmacotherapy for ADHD in adults. Adult Attention Deficit Disorder Conference; Ann Arbor, Mich; May 1994. Google Scholar35. Gualtieri CT. Neuropsychiatry and Behavior Pharmacology. Berlin: Springer-Verlag; 1990:37-89. Google Scholar36. Robinson DR, Bailine S, Alvir J, et al. Pharmacological responses to psychostimulants in borderline and schizotypal personality disorders. Annual Meeting American College of Neuropsychopharmacology; 1989. Google Scholar37. Elia J, Rappoport JL. Ritahn versus dextro-amphetamine in ADHD: should both be tried. In: Greenhill LL, Osman BB, eds. Ritalin: Theory and Patient Management. New York, NY: Mary Ann Liebert Inc; 1991:69-74. Google Scholar38. Werry JS. Pharmacotherapy of disruptive behavior disorders. Child Adolesc Psychiatr Clin North Am. 1994; 3:321-341. Google Scholar39. Ratey JJ, Greenberg MS, Bemporad JR, et al. Unrecognized attention deficit hyperactivity disorder in adults presenting for outpatient psychotherapy. J Child Adolesc Psychopharmacology. 1992; 2;267-275. Google Scholar40. Schatzberg AF, Nemeroff CB. Textbook of Psychopharmacology. 1st ed. Washington, DC: American Psychiatric Press; 1995. Google Scholar41. Rapoport MD, Carlson CA Kelly KL, et al. Methylphenidate and desipramine in ADHD children, I: separate and combined effects on cognitive functions. J Am Acad Child Adolesc Psychiatry. 1993; 32:333-342. Google Scholar42. Wilens TE, Biederman J, Mick E, et al- A systemic assessment of tricyclic antidepressants in the treatment of adult attention deficit hyperactivity disorder. J Nerv Ment Disord. 1995; 183:48-50. Google Scholar43. Rapoport J Childhood behavior and learning problems treated with Imipramine. Int J Neurosci. 1965; :635-642. Google Scholar44. Huessey HR. Imipramine in attention deficit disorder. Am J Psychiatry. 1983; 140:272. Google Scholar45. Wilens TE, Price J, Spencer T, et al. Six week double blind placebo-controDed study of desipramine in adult attention deficit hyperactivity disorder: preliminary results. Am J Psychiatry. 1996; 153:1147-1153. Google Scholar46. Wender PH, Reimherr RW. Buproprion treatment of attention deficit disorder ('minimal brain dysfunction') in adults. Am J Psychiatry. 1990; 147:1018-1023. Google Scholar47. Simeon JG, Ferguson HB, Van Wyck Fleet J. Buproprion effects in attention deficit and conduct disorders. Can J Psychiatry. 1986; 31:581-585. Google Scholar48. Wolfe KD, Weiler EB, Weller RA, et al. Treating children with attention deficit hyperactivity disorder; a douhle blind buproprion trial. Annual Meeting American Academy of Child and Adolescent Psychiatry; San Antonio, Tex; 1993. Google Scholar49. Hedges DW, Reimherr FW, Roger A, et al. An open trial of Venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull. 1995; 31:779-783. Google Scholar50. Adler LA, Resnick S, Kunz M, et al. Open label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull. 1995; 31:785-788. Google Scholar51. Zubieta JK, Alessi NE. Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in childhood. J Clin Psychopharmacol. 1992; 12:346-351. Google Scholar52. Shekim WO, Maaterson A, Cantwell DP, et al. Nomifensine maleate in adult attention deficit disorder. J Nerv Ment Disord. 1989; 177:296-299. Google Scholar53. Barrickman L, Noyes R, Kuperman S, et al. Treatment of attention deficit hyperactivity disorder with fluoxetine; a preliminary trial. J Am Acad Child Adolesc Psychiatry. 1991; 30:762-767. Google Scholar54. Gammons GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacology. 1993; 3:1-10. Google Scholar55. Bussing R, Levin GM. Methamphetamine and fluoxetine treatment of a child with attention deficit hyperactivity disorder and obsessive compulsive disorder. J Child Adolesc Psychopharmacology. 1993; 3:53-58. Google Scholar56. Bhandary AN, Masand PS, Gregory RJ. Obsessive compulsive disorder; combination pharmacotherapy with SSRI and psychostimulants. Annual meeting American Academy of Clinical Psychiatry; San Diego, Calif; October 22, 1995. Google Scholar57. Zametkin AJ, Rapoport JL, Murphy DL1 et al. The treatment of hyperactive children with monoamine oxidase inhibitors. Arch Gen Psychiatry. 1985; 42:962-966. Google Scholar58. Wender PH, Wood D, Reimherr FW, et al. An open trial of pargyline the treatment of attention deficit disorder residual type in adults. Psychiatry Res. 1983; 9:329-336. Google Scholar59. Wood DR, Reimherr FW, Wender PH, et al. The use of LDeprynyl in the treatment of attention deficit disorder residual type (ADD-RT). Psychopharmacol Bull. 1983; 19:627-629. Google Scholar60. Trott GE, Friese HJ, Menzel M, et al. Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology (Beri). 1992; 106(suppl):134-136. Google Scholar61. Hunt RD. Guanfacine in attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995; 34:50-54. Google Scholar62. Mattes J. Propranalol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol. 1986; 6:299-302. Google Scholar63. Bhandary AN, Masand PS. Buspirone in the management of disruptive behaviors. Psychosomatics. In press. Google Scholar64. Balon R. Buspirone for attention deficit hyperactivity disorder. J Clin Psychiatry. 1990; 10:77. Letter. Google Scholar65. Quaison N, Ward D, Kitchen T. Buspirone for aggression. J Am Acad Child Adolesc Psychiatry. 1991; 30:1026. Letter. 66. Google Scholar66. Mitchell WG, Zhou Y, Chavez JM, et al. Effects of antiepileptic drugs on reaction time attention and impulsivity in children. Pediatrics. 1993; 91:101-105. Google Scholar67. Bhandary AN, Fernandez F, Gregory RJ. Treatment strategies in the pharmacological management of adults with attention deficit hyperactivity disorder. Annual meeting of the Institute of Psychiatric Services; Boston, Mass; October 4, 1995. Google Scholar68. Gittleman-Klein R. Childhood disorders. In: Klein D, Quitkin F, Rifkin A, eds. Drug Treatment of Adulthood and Childhood Psychiatric Disorders. Baltimore, Md: Williams & Wilkins; 1980:576-756. Google Scholar69. Shekim WO, Autun F, Hanna GL, et al. S-adenosyl methionine (SAM) in adults with attention deficit hyperactivity disorder-residual type. Psychopharmacol Bull. 1990; 26:249-253. Google Scholar70. Nemzer ED, Arnold LE, Votolato NA, et al. Amino acid plementation as therapy for attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1986; 25:509-513. Google Scholar71. Cocorea JA, Danes RK, Mueller PS, et al. Cocaine and adult attention deficit disorder. J Child Psychiatry. 1987; 48:376-377. Google Scholar72. Reimherr FW, Wood D, Wender PH. An open clinical trial L-Dopa and carbidopa in adults with minimal brain function. Am J Psychiatry. 1980; 137:73-75. Google Scholar73. Defined diets and childhood hyperactivity. Consensus development conference; National Institute of Health; Bethesda, Md; 1982. Google Scholar74. Weiss RD, Pope HG, Mirin SM. Treatment of cocaine abuse and attention deficit disorder, residual type with magnesium pemoline. Drug Alcohol Depend. 1985; 15:69-72. Google Scholar75. Bhandary AN, Pfefferbaum B. Pharmacotherapeutic management of primary nonresponder adults with attention deficit hyperactivity disorder. Annual meeting of the Institute of Psychiatric Services; Chicago, 111; October 1996. Google Scholar Previous article Next article FiguresReferencesRelatedDetails Request Permissions InformationCopyright 2013, SLACK IncorporatedPDF download

Referência(s)
Altmetric
PlumX